Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.52 |
| ▸ | MCHR2 | Q969V1 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411845 | 1.00 | TACR2 (0.53) | TACR2MEN1KMT2APOLBMCHR1 | |
| SCHEMBL5407347 | 0.89 | SMN1; SMN2 (0.55) | TACR2MEN1KMT2APOLBMCHR1 | |
| SCHEMBL5407336 | 0.89 | SMN1; SMN2 (0.55) | TACR2MEN1KMT2APOLBMCHR1 | |
| SCHEMBL5414084 | 0.82 | TACR2 (0.75) | TACR2MCHR1MCHR2 | |
| SCHEMBL5414090 | 0.82 | TACR2 (0.75) | TACR2MCHR1MCHR2 | |
| SCHEMBL5408334 | 0.79 | TACR2 (0.60) | TACR2MEN1KMT2APOLBMCHR1 | |
| SCHEMBL5408341 | 0.79 | TACR2 (0.60) | TACR2MEN1KMT2APOLBMCHR1 | |
| SCHEMBL14519566 | 0.78 | MEN1 (0.52) | TACR2MEN1KMT2APOLBMCHR1 | |
| SCHEMBL8297910 | 0.78 | MEN1 (0.52) | TACR2MEN1KMT2APOLBMCHR1 | |
| SCHEMBL5414437 | 0.77 | TACR2 (0.77) | TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | claimed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | claimed |
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119245-A1 | GlyT2 modulators | GLRB, GLRA1, GLRA2 | TACR2 1302/4885MEN1 1713/4885KMT2A 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.